Multi-Center, Randomized, Open-Label Phase 3 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea.

Trial Profile

Multi-Center, Randomized, Open-Label Phase 3 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Oct 2016

At a glance

  • Drugs T-lymphocyte cell therapy (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Oct 2016 According to media release treatment group achieved extension of PFS by 1.5 times and 30% higher disease control rate (DCR) than control group.
    • 05 Oct 2016 Results published in the Media Release
    • 05 Oct 2016 According to media release, data from this study was published in Oncotarget, a prominent international journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top